Compare Merck & Co., Inc. (MRK) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Merck & Co., Inc. trades at $146 (market cap $351.28B), while iShares 1 3 Year Treasury Bond ETF trades at $81.19 (market cap $26.68B). The key difference: Merck & Co., Inc. is far larger — about 13.2× iShares 1 3 Year Treasury Bond ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while iShares 1 3 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and iShares 1 3 Year Treasury Bond ETF for 63 Days on average.
| MRK | SHY | |
|---|---|---|
Market Cap | $351.28B | $26.68B |
Volume | 7,969,665 | 4,077,691 |
Sector | Health | Fixed Income |
52-Week High | $156.43 | $83.18 |
52-Week Low | $82.49 | $81.05 |
Typical Hold Time | 98 Days | 63 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
SHY trades at $81.185 with minimal daily movement (+0.03%), reflecting stability amid broader bond market volatility. The technical picture shows a bearish trend with moving averages signaling caution, while oscillators remain neutral. Recent dividend payments of $0.24-$0.25 demonstrate consistent income distribution. The fund operates in a challenging environment with rising Treasury yields impacting bond valuations.
SHY faces headwinds from the ongoing bond market selloff and rising interest rates, which pressure short-term bond ETFs. However, the fund's structure provides relative stability compared to longer-duration instruments. The primary risk remains further Fed tightening, while the opportunity lies in capital preservation during market turbulence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
